Sigma-Tau Pharmaceuticals (US Marketing Rights to Defribotide) Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Asset Purch.

  • Financing Rounds
  • 1

Sigma-Tau Pharmaceuticals (US Marketing Rights to Defribotide) General Information

Description

A drug used for the treatment of hepatic veno-occlusive disease. The asset is used for the treatment of severe hepatic veno-occlusive disease which is an early complication in patients undertaking hematopoietic stem cell transplantation therapy.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Buildings and Property
Other Industries
Other Pharmaceuticals and Biotechnology
Pharmaceuticals
Other Devices and Supplies
Corporate Office
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Sigma-Tau Pharmaceuticals (US Marketing Rights to Defribotide) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Sigma-Tau Pharmaceuticals (US Marketing Rights to Defribotide)‘s full profile, request access.

Request a free trial

Sigma-Tau Pharmaceuticals (US Marketing Rights to Defribotide) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Sigma-Tau Pharmaceuticals (US Marketing Rights to Defribotide)‘s full profile, request access.

Request a free trial

Sigma-Tau Pharmaceuticals (US Marketing Rights to Defribotide) FAQs

  • Where is Sigma-Tau Pharmaceuticals (US Marketing Rights to Defribotide) headquartered?

    Sigma-Tau Pharmaceuticals (US Marketing Rights to Defribotide) is headquartered in .

  • What industry is Sigma-Tau Pharmaceuticals (US Marketing Rights to Defribotide) in?

    Sigma-Tau Pharmaceuticals (US Marketing Rights to Defribotide)’s primary industry is Buildings and Property.

  • Is Sigma-Tau Pharmaceuticals (US Marketing Rights to Defribotide) a private or public company?

    Sigma-Tau Pharmaceuticals (US Marketing Rights to Defribotide) is a Private company.

  • What is the current valuation of Sigma-Tau Pharmaceuticals (US Marketing Rights to Defribotide)?

    The current valuation of Sigma-Tau Pharmaceuticals (US Marketing Rights to Defribotide) is 00000.

  • What is Sigma-Tau Pharmaceuticals (US Marketing Rights to Defribotide)’s current revenue?

    The current revenue for Sigma-Tau Pharmaceuticals (US Marketing Rights to Defribotide) is 000000.

  • Who are Sigma-Tau Pharmaceuticals (US Marketing Rights to Defribotide)’s investors?

    Leadiant Biosciences has invested in Sigma-Tau Pharmaceuticals (US Marketing Rights to Defribotide).

  • When was Sigma-Tau Pharmaceuticals (US Marketing Rights to Defribotide) acquired?

    Sigma-Tau Pharmaceuticals (US Marketing Rights to Defribotide) was acquired on 05-Aug-2014.

  • Who acquired Sigma-Tau Pharmaceuticals (US Marketing Rights to Defribotide)?

    Sigma-Tau Pharmaceuticals (US Marketing Rights to Defribotide) was acquired by Jazz Pharmaceuticals.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »